Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…
A phase 1b study showed pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) in patients with previously untreated mRCC. “The risk of death was…
With the growth of immunotherapies in recent years as an effective melanoma treatment option, there are still patients who do not respond well to immunotherapies. Hildur Helgadottir, MD,…
Interim results from the preliminary analysis of the JAVELIN-Renal 101 trial suggest that adding immunotherapy to a targeted agent appears to significantly improve progression-free survival (PFS) when compared with a…
A team of engineers are hoping the 12-sided cage they developed will one day help fight cancer. Made from self-assembling silica, the nanocage is only 11 nanometers across—for…
According to patient recorded outcomes, the IN-Motion151 study met its co-primary endpoint of progression-free survival (PFS). Lead author Bernard Escudier, MD, of the Institut Gustave Roussy in Villejuif, France,…
In a poster presentation at ASCO 2018, authors shared data from a recent study which suggest that testing and modulating the composition of the gut microbiome can have…
In the largest prospective study of angiogenesis in metastatic renal cell carcinoma (mRCC) patients to date, an Italian study yielded data that suggests sorafenib had no meaningful impact…
